Status:

COMPLETED

Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer

Lead Sponsor:

GlaxoSmithKline

Conditions:

Neoplasms, Breast

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This study will examine the inhibition of ErbB1 and ErbB2 phosphorylation and downstream mediators of tumor cell growth and survival tumor tissue in treatment-naive breast cancer patients for three do...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Clinical labs are within acceptable ranges.
  • A histologically confirmed, treatment-naive, breast tumor measuring 1 cm or greater that can be readily biopsied.
  • At least 18 years of age.
  • Females must meet certain criteria specified in protocol.
  • Ability to swallow and retain oral medication.
  • Ability to follow and understand directions.
  • Exclusion criteria:
  • Female who is pregnant or lactating.
  • Medically unfit by the doctor as a result of the medical interview or physicals.
  • Received treatment of an investigational drug within 4 weeks of study start.
  • Currently receiving treatment with prohibited meds listed in protocol.
  • Had major surgery in previous 2 weeks.
  • Had prior radiation therapy to the chest to treat this incidence of breast cancer.
  • Hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study med.
  • Has a malabsorption syndrome.

Exclusion

    Key Trial Info

    Start Date :

    June 29 2004

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    January 9 2008

    Estimated Enrollment :

    28 Patients enrolled

    Trial Details

    Trial ID

    NCT00359190

    Start Date

    June 29 2004

    End Date

    January 9 2008

    Last Update

    November 13 2017

    Active Locations (10)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 3 (10 locations)

    1

    GSK Investigational Site

    Miami, Florida, United States, 33136-1002

    2

    GSK Investigational Site

    Durham, North Carolina, United States, 27710

    3

    GSK Investigational Site

    Allentown, Pennsylvania, United States, 18104

    4

    GSK Investigational Site

    Pittsburgh, Pennsylvania, United States, 15213

    Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer | DecenTrialz